Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Clinical trial NCT05608200 · RECRUITING

Trial details

NCT number: NCT05608200
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Non-resectable

Start date: 2022-11-02
Primary completion: 2026-10-31
Enrollment: 427

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.